Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 65, Issue SUPPL. 1, 2008, Pages 38-46

  Abel, Samantha ^a   Jenkins, Timothy M ^a   Whitlock, Lyndsey A ^a   Ridgway, Caroline E ^a   Muirhead, Gary J ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

CYP3A4; Drug interactions; Inducers; Maraviroc; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A4 INDUCING AGENT; CYTOCHROME P450 3A4 INHIBITOR; EFAVIRENZ; LOPINAVIR; MARAVIROC; PLACEBO; RIFAMPICIN; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG CROSS REACTIVITY; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; LIVER DYSFUNCTION; MALAISE; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PARALLEL DESIGN; PRIORITY JOURNAL; PROTEINASE INHIBITION; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SOMNOLENCE; STUPOR;

EID: 40549086936     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03134.x     Document Type: Article

References (11)

1. 1 Moore JP. Coreceptors: implications for HIV pathogenesis and therapy. Science 1997 ; 276: 51–2.
2. 2 Abel S, Van Der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor‐Worth RJ, Muirhead GJ. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008 ; 65 (Suppl. 1): 5–18.
3. 3 Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA. Species differences in the disposition of the CCR5 antagonist, UK‐427,857, a new potential treatment for HIV. Drug Metab Dispos 2005 ; 33: 587–95.
4. 4 Lin JH, Yamazaki M. Role of P‐glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003 ; 42: 59–98.
5. 5 Bolt HM. Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev 2004 ; 36: 497–509.
6. 6 Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004 ; 44: 1273–81.
7. 7 Berruet N, Sentenac S, Auchere D, Gimenez F, Farinotti R, Fernandez C. Effect of efavirenz on intestinal p‐glycoprotein and hepatic p450 function in rats. J Pharm Pharm Sci 2005 ; 8: 226–34.
8. 8 Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A. Therapeutic drugs that behave as mechanism‐based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004 ; 5: 415–42.
9. 9 Ernest CS 2nd, Hall SD, Jones DR. Mechanism‐based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005 ; 312: 583–91.
10. 10 Abel S, Russell D, Taylor‐Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008 ; 65 (Suppl. 1): 27–37.
11. 11 Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. Ann Pharmacother 1997 ; 31: 1040–58.